secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001171843-23-001339
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus reports FY2022 net loss $69.5M, cash runway into Q4 2024; pipeline milestones set for 2023
--------------------------------------------------------------------------------

- Net loss $69.5M ($0.46/share) vs $88.4M in 2021; revenue $39M up from $11M on Qilu license.
- Cash $184.3M; expects net cash burn $95-100M in 2023, runway into Q4 2024.
- AB-729 Phase 2a data with IFN expected H1 2023; trial with VTP-300 + nivolumab amended.
- Phase 1 trials for oral PD-L1 AB-101 and RNA destabilizer AB-161 to start H1 2023; data H2 2023.
- AB-343 (M pro inhibitor) Phase 1 expected H2 2023; discontinued AB-729+vebicorvir trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323001339/0001171843-23-001339-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323001339/f8k_030223.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-001339

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer